ReShape Lifesciences (NASDAQ:RSLS) Posts Earnings Results, Beats Expectations By $2.17 EPS

ReShape Lifesciences (NASDAQ:RSLS) announced its quarterly earnings results on Friday. The medical device company reported ($1.89) earnings per share (EPS) for the quarter, beating the consensus estimate of ($4.06) by $2.17, Zacks reports. The business had revenue of $1.81 million during the quarter, compared to analyst estimates of $3.17 million. ReShape Lifesciences had a negative return on equity of 179.83% and a negative net margin of 86.36%.

ReShape Lifesciences Price Performance

RSLS stock opened at $0.46 on Friday. The firm has a 50 day moving average of $1.59 and a two-hundred day moving average of $3.99. ReShape Lifesciences has a 12 month low of $0.34 and a 12 month high of $29.00.

About ReShape Lifesciences

ReShape Lifesciences Inc provides products and services that manages and treat obesity and metabolic diseases in the United States, Australia, Europe, and internationally. The company's product portfolio includes Lap-Band System, a minimally invasive long-term treatment of severe obesity and more invasive surgical stapling procedures, such as the gastric bypass or sleeve gastrectomy; Lap-Band 2.0 System, an adjustable postoperatively to increase or decrease the pressure to the band in order to optimize an individual's comfort and therapy effectiveness; and ReShape Calibration Tubes, that fits the lesser curvature of the stomach to reach the pylorus.